Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Implantica

Request full access

Implantable device treating gastroesophageal reflux disease.

SwitzerlandFounded 2003Health Tech & Medtech

About Implantica

Implantica is a medical technology group focused on developing and commercializing implantable devices to treat chronic health conditions. The company was officially founded in 2015 by Dr. Peter Forsell, a specialist surgeon from the Karolinska Institute. Dr. Forsell previously developed the Swedish Adjustable Gastric Band (SAGB) and co-founded Obtech Medical AG, which was sold to Johnson & Johnson. He invested over EUR 85 million from this prior success into Implantica to build out its technology and product pipeline. The company's lead product is RefluxStop™, a CE-marked implant for treating gastroesophageal reflux disease (GERD). Unlike other surgical treatments that encircle the food passageway, RefluxStop™ is designed to restore the natural anatomy by reconstructing the anti-reflux barrier, preventing the lower esophageal sphincter from moving into the thorax. This mechanism addresses the cause of reflux without being associated with common side effects like swallowing difficulties. The device received its CE mark in 2018, and as of September 2025, has been used to treat over 1,400 patients across Europe. The company is publicly listed on the Nasdaq First North Premier Growth Market in Stockholm, having raised SEK 1.265 billion in its September 2020 initial public offering. Implantica's business model centers on the sale of its RefluxStop™ device to hospitals and surgical centers, primarily in Europe, with a focus on establishing centers of excellence. The company operates in the gastrointestinal and urology segments of the MedTech market. Beyond its lead product, Implantica has developed a broad product pipeline based on two platform technologies. The first is a wireless energizing platform to power implants through the skin, and the second is the e-InVivo™ eHealth platform, which allows for remote monitoring, data collection, and control of treatments from inside the body. Future products in development include AppetiteControl™ for obesity and UriControl® for urinary incontinence.

Source: Dealroom company data

At a glance

Status
Listed
Listing
IPO 2020
Outcome tier
Unicorn$1–10B valuation tier

Implantica in its local ecosystem

Live from Dealroom

The Implantica office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Team profiled 4 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 1 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
🇨🇭 Switzerland HQ
Book a demo for the full country breakdown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Implantica on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Implantica on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.